Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Xiang Luo
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07594314CT.gov Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute Anterior Circulation Large Vessel Occlusion (ATTRACTION-MINOA) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Vascular Occlusion Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Minocycline (this asset) | Xiang Luo | P2/3 | B · 57 |
| Atorvastatin | Zhongda Hospital | P4 | BB |
| Compound Edaravone | Beijing Tiantan Hospital | P3 | BB |
| Clevidipine | ProMedica Health System | P3 | BB |
| Tirofiban | Xiang Luo | P2/3 | B |
| Labetalol | Hamilton Health Sciences Corporation | P2 | B |
| Hydralazine | Hamilton Health Sciences Corporation | P2 | B |
| Enalapril | Hamilton Health Sciences Corporation | P2 | B |
Other indications for Minocycline
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mood Disorder | — | P4 | BBB · 73 |
| Bipolar Depression | — | P4 | BB · 70 |
| Schizophrenia | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Minocycline in Vascular Occlusion Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/minocycline-vascular-occlusion-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →